

Daftar Pustaka

- ACTIVE Investigators, Connolly SJ, Pogue J, Hart RG, Hohnloser SH, Pfeffer M, et al. 2009. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. *N Engl J Med*;360:2066-2078.
- Ahammed Z, Kibria A, Babul R, Azam A, Khan J, Absar N, et al. Volume of Intracerebral Hemorrhage: A Powerful Predictor of 30-Day Mortality. :11.
- Ahdy ME, Ghonimi NA, Elserafy TS, Mahmoud W. The NIHSS score can predict the outcome of patients with primary intracerebral hemorrhage. *Egypt J Neurol Psychiatry Neurosurg*. 2019 Dec;55(1):21.
- Alvis-Miranda H, Alcala-Cerra G, Moscote-Salazar LR. Glycemia in Spontaneous Intracerebral Hemorrhage: Clinical Implications. *Romanian Neurosurgery*. 2014 Oct 17;21(3):315–26.
- An SJ, Kim TJ, Yoon B-W. Epidemiology, Risk Factors, and Clinical Features of Intracerebral Hemorrhage: An Update. *J Stroke*. 2017 Jan 31;19(1):3–10.
- An, S.J., Kim, T.J., Yoon, B.-W., 2017. Epidemiology, Risk Factors, and Clinical Features of Intracerebral Hemorrhage: An Update. *J Stroke* 19, 3–10. <https://doi.org/10.5853/jos.2016.00864>
- Annetta MG, Ciancia M, Soave M, Proietti R. Diabetic and nondiabetic hyperglycemia in the ICU. *Current Anaesthesia & Critical Care*. 2006;17(6):385-90. [SEP]
- Appelboom G, Bruce SS, Hickman ZL, Zacharia BE, Carpenter AM, Vaughan KA,

- et al. Volume-dependent effect of perihematoma oedema on outcome for spontaneous intracerebral haemorrhages. *Journal of Neurology, Neurosurgery & Psychiatry*. 2013 May 1;84(5):488–93.
- Aronowski, J., Zhao, X., 2011. Molecular Pathophysiology of Cerebral Hemorrhage: Secondary Brain Injury. *Stroke* 42, 1781–1786. <https://doi.org/10.1161/STROKEAHA.110.596718>
- Becker KL, Nylen ES, White JC, Muller B and Snider RH Jr: Clinical review 167: Procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis: A journey from calcitonin back to its precursors. *J Clin Endocrinol Metab* 89: 1512-1525, 2004.
- Bhasin RR, Xi G, Hua Y, Keep RF, Hoff JT: Experimental intracerebral hemorrhage: effect of lysed erythrocytes on brain edema and blood-brain barrier permeability. *Acta Neurochir Suppl* 2002; 81: 249–251.
- Bos MJ, Koudstaal PJ, Hofman A, Breteler MM. 2007. Decreased glomerular filtration rate is a risk factor for hemorrhagic but not for ischemic stroke: the Rotterdam Study. *Stroke*;38:3127-3132.
- Charidimou A, Kakar P, Fox Z, Werring DJ. 2013. Cerebral microbleeds and recurrent stroke risk: systematic review and meta-analysis of prospective ischemic stroke and transient ischemic attack cohorts. *Stroke* ;44:995-1001.
- Chen S, Zeng L, Hu Z. 2014. Progressing haemorrhagic stroke: categories, causes, mechanisms and managements. *J Neurol* ; 261: 2061– 2078.
- Cheung C, Tsoi T, Hon S, Au-Yeung M, Shiu K, Lee C, et al. Using the National Institutes of Health Stroke Scale (NIHSS) to predict the mortality and outcome of patients with intracerebral haemorrhage. 2008;14(5):5.

Comparison of ABC/2 with the Simplified ABC/2 Formula in Calculating Intracerebral Hemorrhage Volume, 2016. 3.

Cordonnier, C., Demchuk, A., Ziai, W., Anderson, C.S., 2018. Intracerebral haemorrhage: current approaches to acute management. *The Lancet* 392, 1257–1268. [https://doi.org/10.1016/S0140-6736\(18\)31878-6](https://doi.org/10.1016/S0140-6736(18)31878-6)

Cotoi OS, Manjer J, Hedblad B, Engström G, Melander O, Schiopu A (2013) Plasma procalcitonin is associated with all-cause and cancer mortality in apparently healthy men: a prospective population-based study. *BMC Med* 11:180


Davis SM, Broderick J, Hennerici M, Brun NC, Diringer MN, Mayer SA, et al. 2006. Hematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage. *Neurology* ;66:1175-1181.

Delcourt C, Zhang S, Arima H, Sato S, Salman RA-S, Wang X, et al. Significance of Hematoma Shape and Density in Intracerebral Hemorrhage: The Intensive Blood Pressure Reduction in Acute Intracerebral Hemorrhage Trial Study. *Stroke*. 2016 May;47(5):1227–32.

Deng WJ, Shen RL, LiM Teng JF (2015) Relationship between procalcitonin serum levels and functional outcome in stroke patients. *Cell Mol Neurobiol* 35:355–361


Dingxie H, Zhang Y, Zhang B, Jian W, Deng X, Yang Y, et al. Serum Procalcitonin Levels are Associated with Clinical Outcome in Intracerebral Hemorrhage. *Cell Mol Neurobiol*. 2018 Apr;38(3):727–33.

Dingxie H., Zhang, Y., Zhang, B., Jian, W., Deng, X., Yang, Y., Xiao, T., Yu, H., Wen, S., Huang, K., 2018. Serum Procalcitonin Levels are Associated with

- Clinical Outcome in Intracerebral Hemorrhage. *Cell Mol Neurobiol* 38, 727–733. <https://doi.org/10.1007/s10571-017-0538-5>
- El Kassas, G.M., Shehata, M.A., El Wakeel, M.A., Amer, A.F., Elzaree, F.A., Darwish, M.K., Amer, M.F., 2018. Role of Procalcitonin As an Inflammatory Marker in a Sample of Egyptian Children with Simple Obesity. *OAMJMS* 6, 1349–1353. <https://doi.org/10.3889/oamjms.2018.323>
- Feigin VL, Lawes CM, Bennett DA, Barker-Collo SL, Parag V. 2009. Worldwide stroke incidence and early case fatality reported in 56 population-based studies: a systematic review. *Lancet Neurol* ; 8:355-369.
- Flaherty ML, Tao H, Haverbusch M, Sekar P, Kleindorfer D, Kissela B, et al. 2008. Warfarin use leads to larger intracerebral hematomas. *Neurology*;71:1084-1089.
- Flaherty ML, Woo D, Haverbusch M, Sekar P, Khoury J, Sauerbeck L, et al. 2005. Racial variations in location and risk of intracerebral hemorrhage. *Stroke*;36:934-937.
- García-Rodríguez LA, Gaist D, Morton J, Cookson C, González-Pérez A. 2013. Antithrombotic drugs and risk of hemorrhagic stroke in the general population. *Neurology* ;81:566-574.
- Gearhart MM, Parbhoo SK. Hyperglycemia in the critically ill patient. *AACN clinical issues*. 2006 Jan- Mar;17(1):50-5. PubMed PMID: 16462409. 
- Godoy DA, Di Napoli M, Rabinstein AA. Treating hyperglycemia in neurocritical patients: benefits and perils. *Neurocritical care*. 2010 Dec;13(3):425-38. PubMed PMID: 20652767.
- Godoy DA, Rabinstein A, Videtta W, Murillo-Cabezas F. Manejo óptimo de la

- glucemia en el paciente neurocrítico. *Revista de neurologia*. 2010;51:745-56.
- Gu Y, Hua Y, Keep RF, Morgenstern LB, Xi G. 2009. Deferoxamine reduces intracerebral hematoma-induced iron accumulation and neuronal death in piglets. *Stroke*;40:2241–2243.
- Gupta M, Verma R, Parihar A, Garg RK, Singh MK, Malhotra HS. Perihematomal edema as predictor of outcome in spontaneous intracerebral hemorrhage. *Journal of Neurosciences in Rural Practice*. 2014 Jan;5(01):48–54.
- Hakimi, R., Garg, A., 2016. Imaging of Hemorrhagic Stroke 27. *Ann Neurol*;22(5):142-1450
- Hatzistilianou M. 2010. Diagnostic and prognostic role of procalcitonin in infections. *ScientificWorldJournal*. Oct 01;10:1941-6. [[PMC free article](#)] [[PubMed](#)]
- Hegde A, Menon G, Kumar V, Lakshmi Prasad G, Kongwad LI, Nair R, et al. Clinical Profile and Predictors of Outcome in Spontaneous Intracerebral Hemorrhage from a Tertiary Care Centre in South India. *Stroke Research and Treatment*. 2020 Jan 27;2020:1–8.
- Heit, J.J., Iv, M., Wintermark, M., 2017. Imaging of Intracranial Hemorrhage. *J Stroke* 19, 11–27. <https://doi.org/10.5853/jos.2016.00563>
- Higashi Y, Noma K, Yoshizumi M, Kihara Y. Endothelial function and oxidative stress in cardiovascular diseases. *Circulation journal : official journal of the Japanese Circulation Society*. 2009 Mar;73(3):411-8. PubMed PMID: 19194043.
- Ironside, N., Chen, C.-J., Ding, D., Mayer, S.A., Connolly, E.S., 2019.

- Perihematoma Edema After Spontaneous Intracerebral Hemorrhage. *Stroke* 50, 1626–1633. <https://doi.org/10.1161/STROKEAHA.119.024965>
- Jolink WM, Klijn CJ, Brouwers PJ, Kappelle LJ, Vaartjes I. Time trends in incidence, case fatality, and mortality of intracerebral hemorrhage. *Neurology* 2015;85:1318-1324.
- Kang K, Lu J, Ju Y, Wang W, Shen Y, Wang A, et al. Association of pre- and post-stroke glycemic status with clinical outcome in spontaneous intracerebral hemorrhage. *Sci Rep*. 2019 Dec;9(1):19054.
- Kim TJ, Kim CK, Kim Y, Jung S, Jeong HG, An SJ, et al. 2016. Prolonged sleep increases the risk of intracerebral haemorrhage: a nationwide case-control study. *Eur J Neurol* ;23:1036-1043.
- Kim, J.Y., Bae, H.-J., 2017. Spontaneous Intracerebral Hemorrhage: Management. *J Stroke* 19, 28–39. <https://doi.org/10.5853/jos.2016.01935>
- Krishnan, K., Mukhtar, S.F., Lingard, J., Houlton, A., Walker, E., Jones, T., Sprigg, N., Cala, L.A., Becker, J.L., Dineen, R.A., Koumellis, P., Adami, A., Casado, A.M., Bath, P.M.W., Wardlaw, J.M., 2015. Performance characteristics of methods for quantifying spontaneous intracerebral haemorrhage: data from the Efficacy of Nitric Oxide in Stroke (ENOS) trial. *J Neurol Neurosurg Psychiatry* 86, 1258–1266. <https://doi.org/10.1136/jnnp-2014-309845>
- Kurtz P, Claassen J, Helbok R, Schmidt J, Fernandez L, Presciutti M, et al. Systemic glucose variability predicts cerebral metabolic distress and mortality after subarachnoid hemorrhage: a retrospective observational study. *Crit Care*. 2014;18(3):R89.

- Lattanzi S, Cagnetti C, Provinciali L, Silvestrini M (2016) Neutrophil- to-lymphocyte ratio predicts the outcome of acute intracerebral hemorrhage. *Stroke* 47:1654–1657
- Lee S-H, Kim BJ, Bae H-J, Lee JS, Lee J, Park B-J, et al. Effects of glucose level on early and long-term mortality after intracerebral haemorrhage: the Acute Brain Bleeding Analysis Study. *Diabetologia*. 2010 Mar;53(3):429–34.
- Lee SH, Kim BJ, Bae HJ, Lee JS, Lee J, Park BJ, et al. Effects of glucose level on early and long-term mortality after intracerebral haemorrhage: the Acute Brain Bleeding Analysis Study. *Diabetologia*. 2010 Mar;53(3):429-34. PubMed PMID: 20091021. Epub 2010/01/22. eng.
- Lee V, James J, Connors, Sayona J, Katharina M, Sarah Y et al, 2016. Comparison of ABC/2 with the Simplified ABC/2 Formula in Calculating Intracerebral Hemorrhage Volume 3.
- Leno C, Pascual J, Polo JM, Berciano J, Sedano C. Nephrotic syndrome, accelerated atherosclerosis, and stroke. *Stroke* 1992;23(6):921–922. 
- Li YM, Liu XY (2015) Serum levels of procalcitonin and high sensitivity C-reactive protein are associated with long-term mortality in acute ischemic stroke. *J Neurol Sci* 352:68–73
- Lippi G, Sanchis-Gomar F. 2017. Procalcitonin in inflammatory bowel disease: Drawbacks and opportunities. *World J. Gastroenterol*. Dec 21;23(47):8283-8290. [[PMC free article](#)] [[PubMed](#)]
- Mahdy, M.E., Ghonimi, N.A., Elserafy, T.S., Mahmoud, W., 2019. The NIHSS score can predict the outcome of patients with primary intracerebral

- hemorrhage. *Egypt J Neurol Psychiatry Neurosurg* 55, 21.
<https://doi.org/10.1186/s41983-019-0056-0>
- Martini SR, Flaherty ML, Brown WM, Haverbusch M, Comeau ME, Sauerbeck LR, et al. 2012. Risk factors for intracerebral hemorrhage differ according to hemorrhage location. *Neurology* ;79:2275-2282.
- Maruna P, Nedelnikova K, Gurlich R. Physiology and genetics of procalcitonin. 2000. *Physiological Research*. 49:S57-62. PMID:10984072
- Michinaga, S., Koyama, Y., 2015. Pathogenesis of Brain Edema and Investigation into Anti-Edema Drugs. *IJMS* 16, 9949–9975.
<https://doi.org/10.3390/ijms16059949>
- Misbach J, Ali W. Stroke Indonesia: A First Large Prospective Hospital Based Study of Acute Stroke in 28 Hospitals in Indonesia *Journal of Clinical Neuroscience*. 2000 8(3): 245-9
- Misbach J. *Pandangan Umum Mengenai Stroke Dalam: Rasyid A Soertidewi Leditor. Unit Stroke: Manajemen Stroke Secara Komprehensif. Balai Penerbit. Jakarta.2001-17*
- Mracsko E, Veltkamp R (2014) Neuroinflammation after intracerebral hemorrhage. *Front Cell Neurosci* 8:388
- Muller B, White JC, Nyle´n ES, Snider RH, Becker KL, Habener JF (2001) Ubiquitous Expression of the Calcitonin-I Gene in Multiple Tissues in Response to Sepsis. *J Clin Endocrinol Metab* 86:396–404

- Muroi C, Lemb JB, Hugelshofer M, Seule M, Bellut D, Keller E (2014) Early systemic procalcitonin levels in patients with aneurysmal subarachnoid hemorrhage. *Neurocrit Care* 21:73–77
- Mustanoja S, Strbian D, Putaala J, Meretoja A, Curtze S, Haapaniemi E, et al. 2013. Association of prestroke statin use and lipid levels with outcome of intracerebral hemorrhage. *Stroke* ;44:2330-2332.
- Naidech AM, Jovanovic B, Liebling S, Garg RK, Bassin SL, Bendok BR, et al. 2009. Reduced platelet activity is associated with early clot growth and worse 3-month outcome after intracerebral hemorrhage. *Stroke* ;40:2398-2401
- Qutub AA, Hunt CA. Glucose transport to the brain: a systems model. *Brain research Brain research reviews*. 2005 Nov;49(3):595-617. PubMed PMID: 16269321.
- Risikesdes depkes. Proporsi penyebab kematian pada kelompok umur 55-64 tahun menurut tipe daerah, 2008
- . Rizaldy Taslim P, Vincent Ongko W. Complications as Poor Prognostic Factors in Patients with Hemorrhagic Stroke: A Hospital-Based Stroke Registry. *Int J Neurol Neurother* [Internet]. 2020 Feb 5 [cited 2020 Oct 11];7(1). Available from: <https://www.clinmedjournals.org/articles/ijnn/international-journal-of-neurology-and-neurotherapy-ijnn-7-096.php?jid=ijnn>
- Ruolin D, Bo W, Su L, Mingfang W, Jiaofeng H, Yinlian W, et al. 2018. Procalcitonin and Liver Disease: A Literature Review . *JCTH*(7) 51-55. <https://doi.org/10.14218/JCTH.2018.00012>
- Sacco S, Marini C, Toni D, Olivieri L, Carolei A. 2009. Incidence and 10-year survival of intracerebral hemorrhage in a population-based registry. *Stroke*

;40:394-399.

Sansing LH, Kaznatcheeva EA, Perkins CJ, Komaroff E, Gutman FB, Newman GC. Edema after intracerebral hemorrhage: correlations with coagulation parameters and treatment. *J Neurosurg.* 2003; 98:985–992. [PubMed: 12744358]


Saxena A, Anderson CS, Wang X, Sato S, Arima H, Chan E, et al. Prognostic Significance of Hyperglycemia in Acute Intracerebral Hemorrhage: The INTERACT2 Study. *Stroke.* 2016 Mar;47(3):682–8.

Schuetz P, Albrich W, Mueller B. 2011. Procalcitonin for diagnosis of infection and guide to antibiotic decisions: past, present and future. *BMC Med.* 2011;9:107. [[PMC free article](#)] [[PubMed](#)]

Shah GN, Price TO, Banks WA, Morofuji Y, Kovac A, Ercal N, et al. Pharmacological Inhibition of Mitochondrial Carbonic Anhydrases Protects Mouse Cerebral Pericytes from High Glucose-Induced Oxidative Stress and Apoptosis. *The Journal of pharmacology and experimental therapeutics.* 2012 Dec 17. PubMed PMID: 23249625. Epub 2012/12/20. Eng.

Simon L, Gauvin F, Amre D, Saint-Louis P, Lacroix J (2004) Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. *Clin Infect Dis* 39:206–217

Soertidewi L. Hipertensi Sebagai Faktor Stroke. Tesis Magister Epidemiologi Klinik. Universitas Indonesia. 1998

Staykov D, Wagner I, Volbers B, et al. Natural course of perihemorrhagic edema after intracerebral hemorrhage. *Stroke* 2011;42:2625–9. 

- Thrift AG, McNeil JJ, Forbes A, Donnan GA. 1996. Risk factors for cerebral hemorrhage in the era of well-controlled hypertension. Melbourne Risk Factor Study (MERFS) Group. *Stroke*. 27:2020-2025.
- Tomlinson DR, Gardiner NJ. Glucose neurotoxicity. *Nature reviews Neuroscience*. 2008 Jan;9(1):36-45. PubMed PMID: 18094705. [SEP]
- Tuhim S, Dambrosia JM, Price TR, Mohr JP, Wolf PA, Hier DB, et al. Intracerebral hemorrhage: external validation and extension of a model for prediction of 30-day survival. *Ann neurol* 1991; 29: 658-663. [SEP]
- Ulm L, Hoffmann S, Nabavi D, Hermans M, Mackert B, Hamilton F, Schmehl I, Jungehuelsing G, Montaner J, Bustamante A, Katan M, Hartmann A, Ebmeyer S, Dinter C, Wiemer J, Hertel S, Meisel C, Anker S, Meisel A (2017) The randomized controlled STRAWINSKI trial: procalcitonin-guided antibiotic therapy after Stroke. *Front Neurol* 8:153
- Urday S, Beslow LA, Dai F, Zhang F, Battey TWK, Vashkevich A, et al. Rate of Perihematoma Edema Expansion Predicts Outcome After Intracerebral Hemorrhage: *Critical Care Medicine*. 2016 Apr;44(4):790–7.
- Urday, S., Beslow, L.A., Goldstein, D.W., Vashkevich, A., Ayres, A.M., Battey, T.W.K., Selim, M.H., Kimberly, W.T., Rosand, J., Sheth, K.N., 2015. Measurement of Perihematoma Edema in Intracerebral Hemorrhage. *Stroke* 46, 1116–1119. <https://doi.org/10.1161/STROKEAHA.114.007565>
- Uyttenboogaart M, Koch MW, Stewart RE, Vroomen PC, Luijckx G-J, De Keyser J. Moderate hyperglycaemia is associated with favourable outcome in acute lacunar stroke. *Brain*. 2007 Apr 23;130(6):1626–30.

van Asch CJ, Luitse MJ, Rinkel GJ, van der Tweel I, Algra A, Klijn CJ. Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis. *Lancet Neurol* 2010;9:167-176. [SEP]

van Asch CJ, Luitse MJ, Rinkel GJ, van der Tweel I, Algra A, Klijn CJ. Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis. *The Lancet Neurology*. 2010 Feb;9(2):167–76.

van den Berghe G, Wouters P, Weekers F et al (2001) Intensive insulin therapy in the critically ill patients. *N Engl J Med* 345:1359–1367

Vaquero J, Chung C, Blei AT. Cerebral blood flow in acute liver failure: a finding in search of a mechanism. *Metab. Brain Dis.* 2004;19(3–4):177–194. [SEP]

Vassalotti, J.A., Centor, R., Turner, B.J., Greer, R.C., Choi, M., Sequist, T.D., 2016. Practical Approach to Detection and Management of Chronic Kidney Disease for the Primary Care Clinician. *The American Journal of Medicine* 129, 153-162.e7. <https://doi.org/10.1016/j.amjmed.2015.08.025>

Venkatasubramanian C, Mlynash M, Finley-Caulfield A, Eynhorn I, Kalimuthu R, Snider RW, et al. Natural History of Perihematomal Edema After Intracerebral Hemorrhage Measured by Serial Magnetic Resonance Imaging. *Stroke*. 2011 Jan;42(1):73–80.

Vijayan, A.L., Vanimaya, Ravindran, S., Saikant, R., Lakshmi, S., Kartik, R., G, Manoj., 2017. Procalcitonin: a promising diagnostic marker for sepsis and antibiotic therapy. *j intensive care* 5, 51. <https://doi.org/10.1186/s40560-017->

0246-8

Volbers B, Willfarth W, Kuramatsu JB, Struffert T, Dörfler A, Huttner HB, et al.
Impact of Perihemorrhagic Edema on Short-Term Outcome After

Wang C, Gao L, Zhang ZG, Li YQ, Yang YL, Chang T, Zheng LL, Zhang XY, Man
MH, Li LH (2016) Procalcitonin is a stronger predictor of long-term functional
outcome and mortality than high-sensitivity C-reactive protein in patients with
ischemic stroke. *Mol Neurobiol* 53:1509–1517

Wang X, Sun Y, Shao X. Predictive value of procalcitonin for infection of patients
with type- 2 diabetes mellitus. *Exp Ther Med* [Internet]. 2019 May 24 [cited
2020 Sep 1]; Available from: [http://www.spandidos-
publications.com/10.3892/etm.2019.7611](http://www.spandidos-publications.com/10.3892/etm.2019.7611)


Xi G, Keep RF, Hoff JT (2006) Mechanisms of brain injury after intracerebral
haemorrhage. *Lancet Neurol* 5:53–63

Yan L, Wang S, Xu L, Zhang Z, Liao P. Procalcitonin as a prognostic marker
of patients with acute ischemic stroke. *J Clin Lab Anal* [Internet]. 2020 Jul
[cited 2020 Sep 1];34(7). Available from:
<https://onlinelibrary.wiley.com/doi/abs/10.1002/jcla.23301>

Yarkov A, Montero S, Lemus M, Roces de Alvarez- Buylla E, Alvarez-Buylla R.
Arginine-vasopressin in nucleus of the tractus solitarius induces
hyperglycemia and brain glucose retention. *Brain research*. 2001 Jun
1;902(2):212-22. PubMed PMID: 11384615.

Yu Z, Ma L, Zheng J, You C. Prognostic role of perihematoma edema in
intracerebral hemorrhage: a systematic review. *Turkish Neurosurgery*

[Internet]. 2017 [cited 2020 Sep 1]; Available from:
http://www.turkishneurosurgery.org.tr/summary_en_doi.php3?doi=10.5137/1019-5149.JTN.19659-16.0

Zacharia BE, Ducruet AF, Hickman ZL, Grobelny BT, Fernandez L, Schmidt JM, Narula R, Ko LN, Cohen ME, Mayer SA, Connolly ES. Renal dysfunction as an independent predictor of outcome after aneurysmal subarachnoid hemorrhage. *Stroke* 2009;40:2375–2381. 

Zhang Y, Liu G, Wang Y, Su Y, Leak RK, Cao G. Procalcitonin as a Biomarker for Malignant Cerebral Edema in Massive Cerebral Infarction. *Sci Rep*. 2018 Dec;8(1):993.

Zhao X, Sun G, Zhang J, Strong R, Song W, Gonzales N, et al. 2007. Hematom resolution as a target for intracerebral hemorrhage treatment: role for peroxisome proliferator-activated receptor gamma in microglia/macrophages. *Ann Neurol*. ;61:352–362.

Zheng, H., Chen, C., Zhang, J., Hu, Z., 2016. Mechanism and Therapy of Brain Edema after Intracerebral Hemorrhage. *Cerebrovasc Dis* 42, 155–169. <https://doi.org/10.1159/000445170>

Zweifel C, Katan M, Schuetz P, Siegemund M, Morgenthaler NG, Merlo A, Mueller B, Christ-Crain M (2010) Copeptin is associated with mortality and outcome in patients with acute intracerebral hemorrhage. *BMC Neurol* 10:34

LAMPIRAN

1. ANALISIS STATISTIK

Group Statistics

| | Kategori Hematom | N | Mean | Std. Deviation | Std. Error Mean |
|---------------|------------------|----|--------|----------------|-----------------|
| Prokalsitonin | < 30 cc | 24 | .2929 | .11063 | .02258 |
| | >= 30 cc | 8 | 1.2613 | .30944 | .10940 |

Independent Samples Test

| | Levene's Test for Equality of Variances | | t-test for Equality of Means | | | | | | |
|-----------------------------|---|------|------------------------------|-------|-----------------|-----------------|-----------------------|---|---------|
| | F | Sig. | t | df | Sig. (2-tailed) | Mean Difference | Std. Error Difference | 95% Confidence Interval of the Difference | |
| | | | | | | | | Lower | Upper |
| Prokalsitonin | 32.042 | .000 | -13.317 | 30 | .000 | -.96833 | .07272 | -1.11684 | -.81983 |
| Equal variances assumed | | | | | | | | | |
| Equal variances not assumed | | | -8.668 | 7.605 | .000 | -.96833 | .11171 | -1.22829 | -.70838 |

Oneway

Descriptives

Prokalsitonin

| | N | Mean | Std. Deviation | Std. Error | 95% Confidence Interval for Mean | | Minimum | Maximum | Between-Component Variance |
|------------------------|----|--------|----------------|------------|----------------------------------|-------------|---------|---------|----------------------------|
| | | | | | Lower Bound | Upper Bound | | | |
| | | | | | Meninggal < 7 hari | 13 | | | |
| Meninggal 7 - <14 hari | 1 | .3000 | . | . | . | . | .30 | .30 | |
| Meninggal 14 - 21 hari | 2 | 1.4500 | .07071 | .05000 | .8147 | 2.0853 | 1.40 | 1.50 | |
| Hidup | 16 | .2506 | .04973 | .01243 | .2241 | .2771 | .17 | .33 | |
| Total | 32 | .5350 | .46064 | .08143 | .3689 | .7011 | .16 | 1.70 | |
| Model | | | | | | | | | |
| Fixed Effects | | | .32085 | .05672 | .4188 | .6512 | | | |
| Random Effects | | | | .28253 | -.3641 | 1.4341 | | | .18243 |


Test of Homogeneity of Variances

| | | Levene Statistic | df1 | df2 | Sig. |
|---------------|--------------------------------------|------------------|-----|--------|------|
| Prokalsitonin | Based on Mean | 18.387 | 2 | 28 | .000 |
| | Based on Median | 7.944 | 2 | 28 | .002 |
| | Based on Median and with adjusted df | 7.944 | 2 | 12.148 | .006 |
| | Based on trimmed mean | 17.775 | 2 | 28 | .000 |

ANOVA

Prokalsitonin

| | Sum of Squares | df | Mean Square | F | Sig. |
|----------------|----------------|----|-------------|--------|------|
| Between Groups | 3.695 | 3 | 1.232 | 11.965 | .000 |
| Within Groups | 2.883 | 28 | .103 | | |
| Total | 6.578 | 31 | | | |



Area Under the Curve


Test Result Variable(s): Prokalsitonin

| Area | Std. Error ^a | Asymptotic Sig. ^b | Asymptotic 95% Confidence Interval | |
|-------|-------------------------|------------------------------|------------------------------------|-------------|
| | | | Lower Bound | Upper Bound |
| 1.000 | .000 | .000 | 1.000 | 1.000 |

a. Under the nonparametric assumption

b. Null hypothesis: true area = 0.5

ROC Kadar PCT serum terhadap Prognosis



Area Under the Curve

Test Result Variable(s): Prokalsitonin

| Area | Std. Error ^a | Asymptotic Sig. ^b | Asymptotic 95% Confidence Interval | |
|------|-------------------------|------------------------------|------------------------------------|-------------|
| | | | Lower Bound | Upper Bound |
| .871 | .077 | .000 | .719 | 1.000 |

Case Processing Summary

| | Cases | | | | | |
|------------------------------------|-------|---------|---------|---------|-------|---------|
| | Valid | | Missing | | Total | |
| | N | Percent | N | Percent | N | Percent |
| Kategori PCT * Kategori Klinis | 32 | 100.0% | 0 | 0.0% | 32 | 100.0% |
| Kategori Hematom * Kategori Klinis | 32 | 100.0% | 0 | 0.0% | 32 | 100.0% |
| Kategori PHE * Kategori Klinis | 31 | 96.9% | 1 | 3.1% | 32 | 100.0% |

Kategori PCT * Kategori Klinis

Crosstab

| | | | Kategori Klinis | | Total |
|--------------|----------|--------------------------|-----------------|--------|--------|
| | | | Meninggal | Hidup | |
| Kategori PCT | >= 0,325 | Count | 13 | 1 | 14 |
| | | % within Kategori PCT | 92.9% | 7.1% | 100.0% |
| | | % within Kategori Klinis | 81.3% | 6.3% | 43.8% |
| | < 0,325 | Count | 3 | 15 | 18 |
| | | % within Kategori PCT | 16.7% | 83.3% | 100.0% |
| | | % within Kategori Klinis | 18.8% | 93.8% | 56.3% |
| Total | | Count | 16 | 16 | 32 |
| | | % within Kategori PCT | 50.0% | 50.0% | 100.0% |
| | | % within Kategori Klinis | 100.0% | 100.0% | 100.0% |

Chi-Square Tests

| | Value | df | Asymptotic Significance (2-sided) | Exact Sig. (2- sided) | Exact Sig. (1- sided) |
|------------------------------------|---------------------|----|---|--------------------------|--------------------------|
| Pearson Chi-Square | 18.286 ^a | 1 | .000 | | |
| Continuity Correction ^b | 15.365 | 1 | .000 | | |
| Likelihood Ratio | 20.936 | 1 | .000 | | |
| Fisher's Exact Test | | | | .000 | .000 |
| Linear-by-Linear Association | 17.714 | 1 | .000 | | |
| N of Valid Cases | 32 | | | | |

a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 7.00.

b. Computed only for a 2x2 table

Risk Estimate

| | Value | 95% Confidence Interval | |
|---|--------|-------------------------|---------|
| | | Lower | Upper |
| Odds Ratio for Kategori PCT ($\geq 0,325$ / $< 0,325$) | 65.000 | 6.004 | 703.668 |
| For cohort Kategori Klinis = Meninggal | 5.571 | 1.963 | 15.813 |
| For cohort Kategori Klinis = Hidup | .086 | .013 | .573 |
| N of Valid Cases | 32 | | |

2. DATA PRIMER SUBYEK PENELITIAN

| NA MA | US IA (T H) | NO. RM | J K | P C T | HEMA TOM (CC) | NIHSS | | | DARAH RUTIN | | | | | GLUK OSA | FUN GSI GINJ AL | FUNGSI HATI | | | ELEKTROLI T | | | KOAGULASI | | | |
|----------|----------------------|------------|--------|-------------|---------------------|--------------------|----------------------|-----------------------|-----------------------------------|-----------------------|--------------------|----------|----------------------------|------------------------|--------------------------|--|----------|----|----------------|----------|----------|-----------|----------|----------|----------|
| | | | | | | <4 8 JA M | HA RI KE -7 | HA RI KE -14 | HARI KE-21 | W BC (10' 3) | RBC (X1 0'6) | H B | PL T (X 10' 3) | | | DIFF COUNT (NEU/LYMPH/MONO /EO/BASO) | GDS | UR | C R | SG OT | SG PT | N a | K | Cl | PT |
| M | 58 | 8846 39 | L | 0. 96 | 40.5 | 22 | MENINGGAL | | | 12. 6 | 4.26 | .1 | 61 2 | 87.5/7.4/3.2/1.4/0.5 | 201 | 42 | 1. 9 | 26 | 27 | 13 1 | 4. 7 | 10 0 | 11 | 32. 7 | 1. 06 |
| H | 51 | 8834 45 | L | 1. 5 | 45 | 23 | 18 | 25 | MENING GAL (HARI KE -15) | 12. 2 | 4.59 | 14 | 11 5 | 90.8/6.9/2.0/0.1/0.2 | 227 | 155 | 7. 02 | 39 | 27 | 14 9 | 3. 1 | 11 2 | 11. 4 | 26. 3 | 1. 1 |
| AA | 49 | 8864 77 | L | 0. 33 | 23.3 | 12 | 10 | 7 | 5 | 7.7 | 4.8 | .7 | 23 6 | 86.1/6.0/5.8/2.0/0.1 | 143 | 27 | 0. 8 | 42 | 43 | 13 9 | 4. 9 | 10 6 | 11. 2 | 30 | 1 |
| SR | 66 | 7450 99 | P | 0. 3 | 20.7 | 15 | 14 | 12 | 11 | 10. 9 | 4.3 | 12 .6 | 29 4 | 91.3/6.4/2.3/0.0/0.0 | 123 | 27 | 0. 81 | 31 | 43 | 14 1 | 3. 9 | 10 4 | 10. 3 | 22. 4 | 0. 96 |
| MS | 61 | 3485 01 | P | 1. 7 | 68 | 25 | MENINGGAL | | | 20. 1 | 5.44 | .6 | 34 2 | 88.3/7.3/4.2/0.0/0.2 | 144 | 31 | 0. 81 | 43 | 42 | 13 9 | 3. 7 | 95 | 11. 8 | 30. 5 | 1. 02 |
| K | 56 | 8936 14 | P | 0. 2 | 16.07 | 8 | 8 | 6 | 5 | 11. 5 | 5.19 | .5 | 28 5 | 80/12.9/5.1/0.8/0.06 | 153 | 57 | 0. 85 | 47 | 17 | 14 8 | 3. 5 | 10 6 | 11. 4 | 25. 4 | 1. 09 |
| MS | 58 | 9190 43 | L | 1 | 40.9 | 25 | MENINGGAL | | | 12. 6 | 4.67 | .5 | 22 5 | 91.8/5.9/2.0/0.1/0.2 | 167 | 43 | 0. 7 | 40 | 39 | 13 5 | 3. 2 | 99 | 11 | 33 | 1 |
| G | 60 | 9200 97 | L | 0. 16 | 15.8 | 21 | MENINGGAL | | | 17. 8 | 5.11 | .1 | 17 7 | 88/4.8/7.1/0.0/0.1 | 344 | 71 | 1. 3 | 57 | 29 | 14 7 | 4. 3 | 11 2 | 11. 2 | 30 | 1 |
| S | 57 | 9191 12 | P | 0. 25 | 18.3 | 10 | 8 | 6 | 4 | 12. 2 | 4.62 | .4 | 18 9 | 80/11/5/0/0 | 103 | 28 | 0. 7 | 35 | 36 | 13 6 | 3. 7 | 98 | 10. 8 | 22. 7 | 1. 1 |
| S | 60 | 9191 23 | L | 0. 22 | 17.02 | 10 | 8 | 6 | 4 | 11 | 4.2 | .6 | 28 7 | 89/5.4/1.3/0.0/0.0 | 111 | 26 | 0. 9 | 33 | 29 | 14 0 | 4. 4 | 10 0 | 11. 1 | 25. 6 | 1. 05 |
| HS | 55 | 8020 10 | L | 0. 22 | 16.6 | 8 | 7 | 7 | 5 | 12. 4 | 3.32 | 9. 3 | 18 8 | 80/11.4/3.6/3.9/0.7 | 145 | 10 | 0. 7 | 11 | 21 | 14 0 | 4. 3 | 10 3 | 11. 8 | 31. 5 | 1. 04 |
| RS | 58 | 9047 89 | L | 0. 18 | 15.3 | 10 | 8 | 6 | 4 | 11. 5 | 4 | .3 | 24 5 | 85/4.5/1.0/0.0/0.0 | 136 | 28 | 1. 1 | 32 | 34 | 14 2 | 3. 5 | 97 | 10. 7 | 23 | 0. 8 |
| W | 51 | 9189 31 | L | 1. 13 | 41 | 23 | MENINGGAL | | | 17. 3 | 6.3 | .8 | 20 3 | 79.9/13.3/5.5/0.7/0.10 | 215 | 18 | 1. 13 | 55 | 72 | 14 1 | 3. 3 | 10 6 | 103 | 22. 6 | 0. 99 |
| DI | 40 | 8150 42 | P | 1. 53 | 47 | 23 | MENINGGAL | | | 15. 4 | 5.43 | .8 | 19 9 | 81.2/13.5/4.3/0.6/0.4 | 147 | 29 | 1. 5 | 27 | 60 | 13 3 | 3. 3 | 10 6 | 11. 4 | 26. 3 | 1. 1 |
| NB | 59 | 9062 04 | L | 0. 17 | 14.7 | 10 | 7 | 4 | 4 | 11. 1 | 5.49 | .7 | 10 0 | 80.1/13.2/5.6/0.8/0.3 | 109 | 49 | 1. 3 | 65 | 23 | 13 9 | 3. 7 | 95 | 10 | 23 | 0. 89 |
| AH Q | 57 | 9133 89 | L | 0. 3 | 21.15 | 18 | 18 | MENINGGAL | | 15. 7 | 5.33 | .7 | 30 2 | 91.9/4.3/3.7/0.0/0.1 | 155 | 44 | 1. 2 | 15 | 10 | 14 2 | 3. 9 | 10 4 | 10. 4 | 26 | 1 |

| | | | | | | | | | | | | | | | | | | | | | | | | | |
|---------|----|------------|---|----------|-------|----|-----------|----|---------------|----------|------|----------|---------|------------------------|-----|----|----------|-----|----|---------|---------|---------|-----------|----------|----------|
| NM | 63 | 9112 54 | L | 1. 4 | 42.8 | 23 | 22 | 21 | MENING GAL | 18. 9 | 4.22 | 14 .5 | 27 8 | 86.1/7.3/6.2/0.1/0.3 | 300 | 32 | 1 | 18 | 13 | 14 1 | 3. 9 | 10 4 | 11. 17 | 40 | 1. 14 |
| HSN | 57 | 9046 91 | P | 0. 4 | 23 | 19 | MENINGGAL | | | 20 | 5.42 | 15 .6 | 24 2 | 88.3/7.3/4.2/0.0/0.2 | 171 | 39 | 1. 3 | 16 | 35 | 12 9 | 2. 7 | 98 | 11. 1 | 25. 6 | 05 |
| MK | 70 | 2366 43 | L | 0. 3 | 18 | 17 | 16 | 10 | 8 | 6.4 | 3.29 | 9. 8 | 13 2 | 72.2/16.4/9.8/2.6/0.0 | 116 | 49 | 0. 9 | 33 | 20 | 13 7 | 3 | 10 5 | 12 | 24 | 1. 2 |
| LP | 59 | 8623 09 | L | 0. 87 | 39.64 | 21 | MENINGGAL | | | 21. 1 | 4.56 | 15 .9 | 35 5 | 84.2/7.4/5.1/2.5/0.17 | 132 | 29 | 0. 99 | 18 | 13 | 13 6 | 4. 3 | 10 4 | 11. 7 | 31 | 1. 17 |
| J | 50 | 9192 54 | P | 0. 36 | 21.11 | 19 | MENINGGAL | | | 19. 5 | 5.95 | 17 0 | 37 0 | 85.4/9.9/4.5/0.0/0.2 | 143 | 37 | 1. 6 | 113 | 26 | 14 4 | 4 4 | 11 1 | 11. 2 | 25. 6 | 1. 05 |
| MN | 61 | 9189 65 | P | 0. 24 | 18.15 | 9 | 8 | 7 | 6 | 13. 4 | 4.56 | 14 .2 | 25 7 | 85.5/4.5/1.3/0.6/0.0 | 155 | 13 | 0. 7 | 22 | 36 | 13 7 | 3. 7 | 97 | 10. 2 | 22. 7 | 1. 2 |
| MK B | 62 | 9188 66 | L | 0. 32 | 24.25 | 16 | 15 | 13 | 11 | 22. 4 | 4.62 | 15 .4 | 18 9 | 86.0/6.6/5.9/0.9/0.6 | 115 | 30 | 1 | 39 | 27 | 14 5 | 3. 9 | 11 1 | 11. 2 | 30 | 1 |
| MS T | 61 | 9192 67 | P | 0. 27 | 19 | 11 | 10 | 9 | 8 | 13. 5 | 4.56 | 15 .2 | 22 3 | 83.5/4.5/1.3/0.4/0.0 | 143 | 13 | 0. 8 | 22 | 26 | 14 0 | 3. 6 | 97 | 11. 2 | 22. 7 | 1. 2 |
| ES | 48 | 9172 83 | P | 0. 22 | 16.3 | 8 | 7 | 5 | 5 | 11. 5 | 4.3 | 11 .3 | 25 5 | 85/4.5/1.0/0.0/0.0 | 86 | 14 | 0. 68 | 22 | 7 | 13 1 | 4. 7 | 10 0 | 11 | 32. 7 | 1. 06 |
| AW R | 59 | 8900 98 | L | 0. 53 | 25.2 | 19 | MENINGGAL | | | 17 | 5.19 | 16 .1 | 18 7 | 88/4.8/7.1/0.0/0.1 | 189 | 49 | 1. 5 | 27 | 60 | 13 3 | 3. 5 | 10 6 | 11. 2 | 30 | 1 |
| SY | 64 | 9103 03 | L | 0. 53 | 27.1 | 20 | MENINGGAL | | | 19. 8 | 4.67 | 13 .5 | 24 5 | 90.7/4.6/1.1/0.0/0.0 | 99 | 43 | 0. 7 | 35 | 36 | 13 9 | 3. 7 | 98 | 11. 8 | 22. 7 | 1. 1 |
| HT | 60 | 9200 03 | P | 0. 54 | 28.9 | 20 | MENINGGAL | | | 18. 2 | 3.66 | 16 .3 | 18 8 | 87.5/7.4/3.2/1.4/0.5 | 200 | 57 | 0. 85 | 47 | 17 | 14 8 | 3. 5 | 10 6 | 11. 4 | 25. 4 | 1. 09 |
| EAS | 57 | 8850 03 | L | 0. 27 | 18.6 | 12 | 11 | 10 | 8 | 14. 2 | 4.56 | 14 .4 | 20 9 | 88.3/7.3/4.2/0.0/0.2 | 145 | 10 | 0. 7 | 11 | 21 | 14 0 | 4. 3 | 10 3 | 11. 8 | 31. 5 | 1. 04 |
| AP | 59 | 8952 01 | P | 0. 2 | 11 | 22 | MENINGGAL | | | 18. 6 | 4.11 | 16 .1 | 27 7 | 88/4.8/7.1/0.0/0.1 | 350 | 44 | 1. 1 | 43 | 29 | 13 6 | 2. 7 | 96 | 11. 2 | 30 | 1 |
| SH | 60 | 9090 03 | P | 0. 22 | 17.7 | 10 | 8 | 6 | 4 | 11 | 4.2 | 14 9 | 16 9 | 79.9/13.3/5.5/0.7/0.10 | 100 | 28 | 1. 1 | 32 | 34 | 14 2 | 3. 5 | 97 | 10. 7 | 23 | 0. 8 |
| MS | 64 | 9085 67 | L | 0. 3 | 20.6 | 17 | 16 | 14 | 10 | 12. 9 | 3.32 | 10 .9 | 18 8 | 80/11.4/3.6/3.9/0.7 | 98 | 13 | 0. 7 | 22 | 36 | 13 7 | 3. 7 | 97 | 10. 2 | 22. 7 | 1. 2 |

3. REKOMENDASI PERSETUJUAN ETIK



**KEMENTERIAN PENDIDIKAN DAN KEBUDAYAAN
UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN
KOMITE ETIK PENELITIAN KESEHATAN
RSPTN UNIVERSITAS HASANUDDIN
RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR**

Sekretariat : Lantai 3 Gedung Laboratorium Terpadu
JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.
Contact Person: dr. Agussalim Bukhari, MMed, PhD, SpGK, TLP, 081241830858, 0411 5780103, Fax : 0411 581431



REKOMENDASI PERSETUJUAN ETIK
Nomor : 332/UN4.6.4.5.31/PP36/2020

Tanggal: 24 Juni 2020



Dengan Ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

| | | | |
|---|---|---|------------------------------|
| No Protokol | UH20050222 | No Sponsor Protokol | |
| Peneliti Utama | dr. Maria Caroline Wojtyla | Sponsor | |
| Judul Peneliti | Pengaruh Kadar Procalcitonin Serum dengan Volume Hematom, Edema Perihematom, dan Derajat Klinis Pasien Strok Perdarahan Intraserebral | | |
| No Versi Protokol | 2 | Tanggal Versi | 15 Juni 2020 |
| No Versi PSP | 2 | Tanggal Versi | 15 Juni 2020 |
| Tempat Penelitian | RSUP Dr Wahidin Sudirohusodo Makassar | | |
| Jenis Review | <input type="checkbox"/> Exempted <input checked="" type="checkbox"/> Expedited <input type="checkbox"/> Fullboard | Masa Berlaku 24 Juni 2020 Sampai 24 Juni 2021 | Frekuensi review lanjutan |
| Ketua Komisi Etik Penelitian Kesehatan FK UH | Nama Prof.Dr.dr.Suryani As'ad.,MSc,Sp.GK (K) | Tanda tangan  | Tanggal |
| Sekretaris Komisi Etik Penelitian Kesehatan FK UH | Nama dr. Agussalim Bukhari, M.Med, PhD, Sp.GK (K) | Tanda tangan  | Tanggal |

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 jam dan dilengkapi dalam 7 hari dan Laporan SUSAR dalam 72 jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari prokol yang disetujui (protocol deviation / violation)
- Menatuhi semua peraturan yang ditentukan

4. FORMULIR PERSETUJUAN MENGIKUTI PENELITIAN



KEMENTERIAN RISET, TEKNOLOGI, DAN PENDIDIKAN
TINGGI

UNIVERSITAS HASANUDDIN
FAKULTAS KEDOKTERAN
KOMITE ETIK PENELITIAN KESEHATAN
Sekretariat : Lantai 2 Gedung Laboratorium Terpadu
Jl. JL. PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM. 10,
Makassar 90245
Contact Person: dr. Agus Salim Bukhari, MMed, PhD, SpGK, email: agusalim@j
yahoo.com

Lampiran 2.

FORMULIR PERSETUJUAN MENGIKUTI PENELITIAN

Saya yang bertanda tangan di bawah ini :

Nama :

Umur:

Alamat:

setelah mendengar/membaca dan mengerti penjelasan yang diberikan mengenai tujuan, manfaat apa yang akan dilakukan pada penelitian ini, menyatakan setuju untuk ikut dalam penelitian ini.

Saya tahu bahwa keikutsertaan saya ini bersifat sukarela tanpa paksaan, sehingga saya bisa menolak ikut atau mengundurkan diri dari penelitian ini tanpa kehilangan hak saya untuk mendapat pelayanan kesehatan. Juga saya berhak bertanya atau meminta penjelasan pada peneliti bila masih ada hal yang belum jelas atau masih ada hal yang ingin saya ketahui tentang penelitian ini.

Saya juga mengerti bahwa semua biaya yang dikeluarkan sehubungan dengan penelitian ini, akan ditanggung oleh BPJS dan biaya mandiri. Adapun biaya perawatan dan pengobatan bila terjadi hal-hal yang tidak diinginkan akibat penelitian ini, akan dibiayai oleh peneliti.

Saya percaya bahwa keamanan dan kerahasiaan data penelitian akan terjamin dan saya dengan ini menyetujui semua data saya yang dihasilkan pada penelitian ini untuk disajikan dalam bentuk lisan maupun tulisan.

Bila terjadi perbedaan pendapat dikemudian hari kami akan menyelesaikannya secara kekeluargaan.

13



NAMA HUBUNGAN TANDA TANGAN TGL/BLN/THN
DENGAN PASIEN

Klien

Saksi 1

Saksi 2

| Penanggung Jawab Penelitian | Penanggung Jawab Medis |
|-------------------------------|--|
| Nama : Maria Caroline Wojtyla | Nama : Dr. dr. David Gunawan |
| Alamat : BTP Blok L no 27 | Umbas, Sp.S (K) |
| Telepon : 082393383030 | Alamat : Perumahan angin mamiri Blok D5 No. 5-6 |
| | Telepon : 081342379881 |

5. DOKUMENTASI PELAKSANAAN OLAH SAMPEL PENELITIAN



